Nevirapine-induced fulminant hepatitis

Journal of Association of Physicians of India

Volumn 54, Issue DEC., 2006, Pages 957-958

  Maniar, J K ^a   Shah, S R ^a   Verma, Reena ^a   Kamath, R ^b   Gupte, P ^a   Maniar, A ^b  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^b Dr Maniar's ID Clinic   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FATALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MALE; MORTALITY; RISK FACTOR;

ADULT; ANTI-RETROVIRAL AGENTS; FATAL OUTCOME; HIV INFECTIONS; HUMANS; LIVER FAILURE, ACUTE; MALE; NEVIRAPINE; RISK FACTORS;

EID: 33947587708     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Orenstein R, Tsago N. Looking beyond HAART: drug-related hepatotoxicity in patients with human immunodeficiency virus infection. Pharmacotherapy 2002;22:1468-78.
2. De Maat MM, Ter Heine R, Van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003;17:2209-14.
3. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
4. Stern J, Robinson P, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different population of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S21-33.
5. st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires), 2001.